# US 6,355,246 B1 · Feline calicivirus isolated from cat urine and vaccines thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,355,246 B1 - Document ID: US6355246B1 - Status: Granted - Kind: B1 - Application number: 09/590,020 - Filed: 2000-06-08 - Granted: 2002-03-12 - Earliest claimed: 1999-06-10 - Assignees: Board of Trustees of Michigan State University - Inventors: John M. Kruger; Roger K. Maes; Aivars Vilnis - Web page: https://patentgrep.com/patent/US6355246B1 ## CPC - C07K 14/005: from viruses - A61K 39/12: Viral antigens - A61K 39/125: Picornaviridae, e.g. calicivirus - A61P 13/00: Drugs for disorders of the urinary system - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61K 2039/5254: {avirulent or attenuated} - C12N 2770/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2770/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2770/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention provides an isolated feline calicivirus and mutants thereof, which were isolated from the urine of a cat with lower urinary tract disorder. The present invention further provides nucleic acid clones of the virus, in particular, a clone which encodes the capsid antigen of the virus. The present invention is useful for providing a live or killed virus vaccine comprising the virus or mutants thereof, a subunit vaccine comprising the capsid antigen of the virus, a nucleic acid vaccine encoding the capsid antigen of the virus, and a recombinant virus vector vaccine encoding the capsid antigen of the virus. The present invention also provides a method for isolating feline calicivirus from urine and an assay for diagnosing cats infected with feline calicivirus. ## Claims ### Claim 1 A vaccine for immunizing cats against feline calicivirus comprising: FCV-U1 or mutant thereof, in an effective amount to produce an immune response, and a pharmaceutically acceptable carrier. ### Claim 2 (depends on 1) The vaccine of claim 1 containing an adjuvant. ### Claim 3 (depends on 1, 2) The vaccine of claim 1 or 2, wherein the FCV-U1 or mutant thereof is live. ### Claim 4 (depends on 1, 2) The vaccine of claim 1 or 2, wherein the FCV-U1 or mutant thereof is attenuated. ### Claim 5 (depends on 1, 2) The vaccine of claim 1 or 2, wherein the FCV-U1 or mutant thereof is inactivated. ### Claim 6 (depends on 1, 2) The vaccine of claim 1 or 2, comprising the FCV-U2 or mutant thereof and at least one feline calicivirus strain selected from the group consisting of FCV-U2, FCV-F9, FCV-LLK, FCV-M8, FCV-255, and FCV-2280, in addition to the FCV-U1 or mutant thereof. ### Claim 7 A vaccine for immunizing cats against feline calicivirus comprising: FCV-U2 or mutant thereof, in an effective amount to produce an immune response, and a pharmaceutically acceptable carrier. ### Claim 8 (depends on 7) The vaccine of claim 7 containing an adjuvant. ### Claim 9 (depends on 7, 8) The vaccine of claim 7 or 8, wherein the FCV-U2 or mutant thereof is live. ### Claim 10 (depends on 7, 8) The vaccine of claim 7 or 8, wherein the FCV-U2 or mutant thereof is attenuated. ### Claim 11 (depends on 7, 8) The vaccine of claim 7 or 8, wherein the FCV-U2 or mutant thereof is inactivated. ### Claim 12 (depends on 7, 8) The vaccine of claim 7 or 8, comprising the FCV-U2 or mutant thereof and at least one feline calicivirus strain selected from the group consisting of FCV-U1, FCV-F9, FCV-LLK, FCV-M8, FCV-255, and FCV-2280, in addition to the FCV-U2or mutant thereof. ### Claim 13 A method for immunizing a cat against feline calicivirus comprising: administering to the cat an effective dose of a vaccine selected from the group consisting of a live FCV-U1 or mutant thereof and a killed FCV-U1 or mutant thereof, in a pharmaceutically acceptable carrier. ### Claim 14 (depends on 13) The method of claim 13, wherein the capsid antigen or immunogenic fragment thereof comprises the amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6. ### Claim 15 (depends on 13) The method of claim 13, wherein the nucleotide sequence comprises the nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5. ### Claim 16 A method for immunizing a cat against feline calicivirus comprising: administering to the cat an effective dose of a vaccine selected from the group consisting of a live FCV-U2 or mutant thereof and a killed FCV-U2 or mutant thereof, in a pharmaceutically acceptable carrier. ### Claim 17 An isolated and purified culture of feline calicivirus FCV-UV1 or mutant thereof deposited as ATCC PTA-3444. ### Claim 18 An isolated and purified culture of feline calicivirus FCV-UV2 or mutant thereof deposited as ATCC PTA-3445.